NZ600505A - Hepatitis c virus inhibitors - Google Patents

Hepatitis c virus inhibitors

Info

Publication number
NZ600505A
NZ600505A NZ600505A NZ60050510A NZ600505A NZ 600505 A NZ600505 A NZ 600505A NZ 600505 A NZ600505 A NZ 600505A NZ 60050510 A NZ60050510 A NZ 60050510A NZ 600505 A NZ600505 A NZ 600505A
Authority
NZ
New Zealand
Prior art keywords
compounds
hepatitis
virus
benzimidazol
pyrrolidinyl
Prior art date
Application number
NZ600505A
Other languages
English (en)
Inventor
Rico Lavoie
Piyasena Hewawasam
Qi Chen
Gan Wang
Omar D Lopez
Zhong Yang
Makonen Belema
John A Bender
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43466793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ600505(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NZ600505A publication Critical patent/NZ600505A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
NZ600505A 2009-11-11 2010-11-05 Hepatitis c virus inhibitors NZ600505A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26011509P 2009-11-11 2009-11-11
US37880610P 2010-08-31 2010-08-31
PCT/US2010/055565 WO2011059887A1 (en) 2009-11-11 2010-11-05 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
NZ600505A true NZ600505A (en) 2013-12-20

Family

ID=43466793

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600505A NZ600505A (en) 2009-11-11 2010-11-05 Hepatitis c virus inhibitors

Country Status (21)

Country Link
US (6) US20110274648A1 (OSRAM)
EP (1) EP2499127B1 (OSRAM)
JP (1) JP2013510853A (OSRAM)
KR (1) KR20130036173A (OSRAM)
CN (1) CN102712623B (OSRAM)
AR (1) AR078976A1 (OSRAM)
AU (1) AU2010319801A1 (OSRAM)
BR (1) BR112012011100A2 (OSRAM)
CA (1) CA2780812A1 (OSRAM)
CL (1) CL2012001230A1 (OSRAM)
EA (1) EA201270622A1 (OSRAM)
ES (1) ES2690660T3 (OSRAM)
IL (1) IL219516A (OSRAM)
MA (1) MA33731B1 (OSRAM)
MX (1) MX2012005190A (OSRAM)
NZ (1) NZ600505A (OSRAM)
PE (1) PE20121354A1 (OSRAM)
PH (1) PH12012500922A1 (OSRAM)
TN (1) TN2012000214A1 (OSRAM)
TW (1) TWI475019B (OSRAM)
WO (1) WO2011059887A1 (OSRAM)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0922366B8 (pt) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734956B2 (ja) * 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
MX363732B (es) 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011081918A1 (en) * 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011149937A1 (en) * 2010-05-24 2011-12-01 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
DK2585467T3 (en) 2010-06-24 2016-06-13 Gilead Sciences Inc PYRAZOLO [1,5-A] PYRIMIDINES AND TRIAZINES AS ANTIVIRAL AGENTS
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
EP2730572B1 (en) 2011-07-09 2015-09-16 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
BR112014010401A8 (pt) 2011-11-03 2017-12-19 Theravance Inc Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
AU2012358805B2 (en) 2011-12-22 2017-07-20 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2013217224B2 (en) 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
PT2838900T (pt) 2012-04-17 2019-11-15 Gilead Sciences Inc Compostos e métodos para tratamento antiviral
JP6069491B2 (ja) 2012-04-25 2017-02-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｃ型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
JP6006008B2 (ja) * 2012-06-14 2016-10-12 ユー・ディー・シー アイルランド リミテッド 化合物、有機電界発光素子並びに該有機電界発光素子を用いた発光装置、表示装置及び照明装置
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
EP3328839A1 (en) * 2015-07-30 2018-06-06 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BR112018071678B1 (pt) 2016-08-19 2021-01-26 Gilead Sciences, Inc. compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
CN117460734A (zh) 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物
WO2022246072A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
EP4440702B1 (en) 2021-12-03 2025-05-21 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
EP4440701A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679153A4 (en) 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2348332T3 (es) 2005-09-16 2010-12-02 Arrow Therapeutics Limited Derivados de bifenilo y su uso en el tratamiento de la hepatitis c.
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
BRPI0712806A2 (pt) 2006-05-30 2012-10-23 Arrow Therapeutics Ltd uso de um composto, derivado de bifenila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, produto, e, método para melhorar uma infecção por hepatite c em um paciente
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2097405A2 (en) 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
DE102007057622A1 (de) * 2007-11-30 2009-06-04 Stechert Stahlrohrmöbel GmbH Klappstuhl
CA2715400A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Heterocyclic derivatives as hepatitis c virus inhibitors
KR101468765B1 (ko) 2008-02-12 2014-12-04 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제
ES2391600T3 (es) 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
SG171890A1 (en) * 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
BRPI0922366B8 (pt) * 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
EP2393359A4 (en) * 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
MX2011008982A (es) * 2009-02-27 2011-09-15 Enata Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
KR101387274B1 (ko) 2009-03-27 2014-04-25 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 복제의 억제제
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
RU2528231C2 (ru) 2009-04-24 2014-09-10 Тиботек Фармасьютикалз Диариловые эфиры
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
MX363732B (es) * 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010253790A1 (en) 2009-05-29 2011-12-15 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
EP2473503B1 (en) 2009-09-03 2014-07-23 Janssen R&D Ireland Bis-benzimidazole derivatives
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2010325980B2 (en) 2009-12-04 2016-04-07 National Health Research Institutes Proline derivatives
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
WO2011091532A1 (en) 2010-01-28 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CA2794145A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2575866A4 (en) * 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
TW201121955A (en) 2011-07-01
EA201270622A1 (ru) 2012-12-28
US20130115193A1 (en) 2013-05-09
US20150197499A1 (en) 2015-07-16
WO2011059887A1 (en) 2011-05-19
BR112012011100A2 (pt) 2019-09-24
PE20121354A1 (es) 2012-10-15
IL219516A0 (en) 2012-06-28
EP2499127B1 (en) 2018-09-05
CN102712623B (zh) 2014-04-02
US9303007B2 (en) 2016-04-05
IL219516A (en) 2015-09-24
US20150322048A1 (en) 2015-11-12
MA33731B1 (fr) 2012-11-01
US20170355689A1 (en) 2017-12-14
US20150322031A1 (en) 2015-11-12
AR078976A1 (es) 2011-12-14
CN102712623A (zh) 2012-10-03
US9776981B2 (en) 2017-10-03
KR20130036173A (ko) 2013-04-11
US20110274648A1 (en) 2011-11-10
EP2499127A1 (en) 2012-09-19
JP2013510853A (ja) 2013-03-28
MX2012005190A (es) 2012-06-08
CA2780812A1 (en) 2011-05-19
CL2012001230A1 (es) 2012-09-28
ES2690660T3 (es) 2018-11-21
TWI475019B (zh) 2015-03-01
AU2010319801A1 (en) 2012-06-28
PH12012500922A1 (en) 2012-11-26
TN2012000214A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
NZ600505A (en) Hepatitis c virus inhibitors
NZ594981A (en) Hepatitis c virus inhibitors
PE20120533A1 (es) Inhibidores del virus de la hepatitis c
NZ595168A (en) Hepatitis c virus inhibitors
PE20160800A1 (es) Combinacion de metil ((1s)-1-(((2s)-2-(5-(4’-(2-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il-1-pirrolidinil)carbonil)-2-metilpropil)carbamato (daclatasvir) y n-(tert-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida (asunaprevir).
HRP20120440T1 (hr) Inhibitori virusa hepatitisa c
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
HRP20160410T1 (hr) Inhibitori hepatitis c virusa
NZ606645A (en) Anti-viral compounds
MX2010001415A (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c.
DOP2011000298A (es) Metilo[(2s)-1-{(2s)-2-[5-(10-{2-[(2s)-1-{(2s)-2-[(metoxicarbonil) amino]-3- metilbutanoilo} pirrolidina-2-yl]-1h-imidazol-5-yl}-6-fenilindol[1,2-c][1,3] benzoxazin-3-yl)-1h-imidazol-2-yl]pirrolidina-1-yl} -3-metilo-1-oxobutan-2-yl]carbamato y uso del mismo para tratar la infección por vhc
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
NZ596107A (en) Antiviral compounds and methods
EA200900697A1 (ru) Ингибиторы вируса гепатита с
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
NZ710567A (en) Antiviral compounds
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
EA200800670A1 (ru) Ингибиторы сериновых протеаз
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
HN2011000209A (es) Compuestos macrociclicos de quinoxalina como inhibidores de la proteasa ns3 de vhc
UA116616C2 (uk) Інгібітори hcv серинової протеази, отримані з макроциклічного проліну
MX2009009174A (es) Inhibidores de serina-proteasas para el tratamiento de infecciones por el virus de hepatitis c.
WO2010034105A8 (en) Hepatitis c inhibitor compounds
WO2012019299A9 (en) Hepatitis c inhibitor compounds
ATE440833T1 (de) Antithrombotische diamide

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2015 BY CPA GLOBAL

Effective date: 20141002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2016 BY CPA GLOBAL

Effective date: 20151002

LAPS Patent lapsed